

HARVARD BIOSCIENCE INC  
 Form 4  
 November 05, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**LUSCINSKI SUSAN M**

2. Issuer Name and Ticker or Trading Symbol  
**HARVARD BIOSCIENCE INC [HBIO]**

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
**84 OCTOBER HILL ROAD**  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**11/01/2013**

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
**Chief Operating Officer**

**HOLLISTON, MA 01746**  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (D)  | Price                             |
| Common Stock                    | 11/01/2013                           |  | J                              |   | 24,201<br>(1)   | A  | \$ 0                              |
|                                 |                                      |  |                                |   | 469,720   | (2)  | D                                 |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: HARVARD BIOSCIENCE INC - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |     | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |  |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|---|-------------------------------|--|----------------------------|
|  |  |                                      |  | Code                           | V   | (A)  | (D) | Date Exercisable  | Expiration Date               | Title                                    | Amount or Number of Shares |
| Stock option (right to buy)                | \$ 5.73  | 11/01/2013                           |  | J                              |   | 35,757<br><u>(1)</u>                                     |     | <u>(3)</u>  | 03/25/2014                    | Common Stock, par value \$0.01 per share | 35,757                     |
| Stock option (right to buy)                | \$ 2.14  | 11/01/2013                           |  | J                              |   | 11,996<br><u>(1)</u>                                     |     | <u>(4)</u>  | 05/25/2015                    | Common Stock, par value \$0.01 per share | 11,996                     |
| Stock option (right to buy)                | \$ 3.07  | 11/01/2013                           |  | J                              |   | 19,799<br><u>(1)</u>                                     |     | <u>(5)</u>  | 08/09/2016                    | Common Stock, par value \$0.01 per share | 19,799                     |
| Stock option (right to buy)                | \$ 3.99  | 11/01/2013                           |  | J                              |   | 31,723<br><u>(1)</u>                                     |     | <u>(6)</u>  | 05/01/2017                    | Common Stock, par value \$0.01 per share | 31,723                     |
| Stock option (right to buy)                | \$ 2.28  | 11/01/2013                           |  | J                              |   | 48,543<br><u>(1)</u>                                     |     | <u>(7)</u>  | 05/21/2019                    | Common Stock, par value \$0.01 per share | 48,543                     |
| Stock option (right to buy)                | \$ 4.04  | 11/01/2013                           |  | J                              |   | 11,888<br><u>(1)</u>                                     |     | <u>(8)</u>  | 06/02/2021                    | Common Stock, par value \$0.01 per share | 11,888                     |
| Stock option (right to buy)                | \$ 2.56  | 11/01/2013                           |  | J                              |   | 25,098<br><u>(1)</u>                                     |     | <u>(9)</u>  | 06/01/2022                    | Common Stock, par value \$0.01 per share | 25,098                     |
|  | \$ 3.64  | 11/01/2013                           |  | J                              |   |  |     | <u>(10)</u>   | 05/31/2023                    |  | 11,806                     |

|                             |                      |  |
|-----------------------------|----------------------|--|
| Stock option (right to buy) | 11,806<br><u>(1)</u> | Common Stock, par value \$0.01 per share |
|-----------------------------|----------------------|--|

## Reporting Owners

| Reporting Owner Name / Address                                   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| LUSCINSKI SUSAN M<br>84 OCTOBER HILL ROAD<br>HOLLISTON, MA 01746 |               |           | Chief Operating Officer |       |

## Signatures

Susan M.  
Luscinski

11/05/2013

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These additional options and restricted stock units were acquired by the Reporting Person in connection with the adjustment to the existing options and restricted stock units held by the Reporting Person and required in connection with the spin-off of Harvard Apparatus Regenerative Technology, Inc. by the Issuer. As part of such required adjustment relating to the spin-off, the exercise price of the options underlying these adjustment option grants was also reset to the exercise price of these adjustment grants to reflect the impact of the spin-off. The share amounts and exercise prices of the adjusted options and restricted stock units were set in a manner to ensure the intrinsic value held by the Reporting Person pertaining to the existing award was maintained immediately following the spin-off. In addition to these adjustments, to maintain such intrinsic value, equity awards issued by Harvard Apparatus Regenerative Technology, Inc. were also granted to the Reporting Person.

- (2) Includes (a) an adjusted deferred stock award of 21,992 restricted stock units which shall vest on Jan 1, 2014; (b) an adjusted deferred stock award of 12,347 restricted stock units which vest in equal installments on Jan 1, 2014 and Jan 1, 2015; (c) an adjusted deferred stock award of 40,764 restricted stock units which vest in equal installments on Jan 1, 2014, Jan 1, 2015, and Jan 1, 2016; (d) an adjusted deferred stock award of 25,465 restricted stock units which vest in equal installments on Jan 1, 2014, Jan 1, 2015, Jan 1, 2016, and Jan 1, 2017; and (e) 369,152 shares of common stock held by the Reporting Person.
- (3) The option shares vested in four equal installments on January 1, 2005, 2006, 2007 and 2008.
- (4) The option shares vested in four equal installments on January 1, 2006, 2007, 2008 and 2009.
- (5) The option shares vested in four equal installments on January 1, 2007, 2008, 2009 and 2010.
- (6) The option shares vested in four equal installments on January 1, 2008, 2009, 2010 and 2011.
- (7) The option shares vested in four equal installments on January 1, 2010, 2011, 2012 and 2013.
- (8) The unvested shares become exercisable in equal installments on January 1 of each of 2014 and 2015.
- (9) The unvested shares become exercisable in equal installments on January 1 of each of 2014, 2015 and 2016.
- (10) The unvested shares become exercisable in equal installments on January 1 of each of 2014, 2015, 2016 and 2017.

### Remarks:

This form has been signed under power of attorney.

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.